| May 30 |
Summit Shares Soar After Cancer Drug Tops Merck’s Keytruda
|
| May 30 |
Competitor to Merck's Keytruda Worries Some Investors
|
| May 30 |
Summit lead asset beats Merck’s Keytruda in a first in lung cancer
|
| May 30 |
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
|
| May 28 |
Why Summit Therapeutics Stock Is Sinking Today
|
| May 24 |
Summit Therapeutics Shares Fall After Late-Stage Topline Data for Lung Cancer Treatment Announced
|
| May 24 |
Summit Therapeutics falls after late-stage data for lead asset
|
